World's Largest Cruise Ship to Make Maiden Voyage From Florida
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
The largest cruise ship in the world is set to make its maiden voyage in August.
Royal Caribbean welcomed its newest Icon-class vessel, the Star of the Seas, ahead of its inaugural journey from Port Canaveral, Florida, on August 31.
Newsweek reached out to Royal Caribbean via email for comment.
The Context
The Star of the Seas will become the sister ship to the Icon of the Seas, which launched in January last year. They are the same size, at 248,633 gross tonnage, and will share the mantle of the largest cruise ship in the world. Construction on the Star of the Seas began in 2023 and was finished on September 25, 2024.
A rendering of the Star of the Seas, which begins its maiden voyage in August this year.
A rendering of the Star of the Seas, which begins its maiden voyage in August this year.
Royal Caribbean
What To Know
The 5,610-passenger ship, constructed over nearly two years at the Meyer Turku shipyard in Finland, completed sea trials involving more than 2,000 maritime experts.
The ship will commence weeklong eastern and western Caribbean sailings, including stops at Royal Caribbean's private Bahamas resort, Perfect Day at CocoCay.
For testing, the ship underwent rigorous 11-day sea trials in Finland, reaching speeds of up to 25 knots while engineers measured propulsion, pressure, and maneuverability.
A rendering of the Star of the Seas, which begins its maiden voyage in August this year.
A rendering of the Star of the Seas, which begins its maiden voyage in August this year.
Royal Caribbean
As part of its environmental strategy, Star of the Seas uses LNG fuel, widely regarded as a cleaner maritime alternative. It incorporates systems that recover waste heat and enable shore power connections, reducing emissions while docked.
The maiden voyage will depart from Port Canaveral on August 31, 2025, for a seven-night cruise around the western Caribbean. Fares for this sailing start at about $1,731 per person, according to The Independent. In advance, shorter showcase journeys include a three-night round-trip to Perfect Day at CocoCay, beginning August 20, with tickets from about $1,069 per person, the outlet reported.
What People Are Saying
Jason Liberty, president and CEO, Royal Caribbean Group, said in a July 2025 statement: "The delivery of Star of the Seas marks another bold step forward in Royal Caribbean Group's journey to reimagine the future of vacations.
"Star and the Icon class are a symbol of what's possible when innovation, imagination and our relentless focus on delivering exceptional experiences come together, ultimately creating unforgettable memories for millions of families and vacationers.
"We're proud to bring this next-generation vacation experience to life with our valued partners at Meyer Turku."
Michael Bayley, president and CEO, Royal Caribbean International, said in July 2025: "We're incredibly proud to welcome Star of the Seas to the Royal Caribbean family as we continue to revolutionize how families and adventurers vacation.
"It's a true team effort with so many talented individuals coming together to make the new Icon class vacation a reality, and we're excited to debut this incredible achievement with a star-studded celebration this August."
What Happens Next
Following final preparations in Cadiz, Spain, Star of the Seas is scheduled to begin regular seven-night cruises from Port Canaveral in August 2025, with additional short showcase cruises planned. Royal Caribbean aims to debut its next Icon-class ship, Legend of the Seas, in 2026.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
3 hours ago
- Newsweek
FDA Suspends Muscular Dystrophy Drug After 3 Patient Deaths
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments. The agency announced the action on Friday, citing serious safety concerns and "unreasonable and significant risk" to study participants. The FDA also revoked the company's platform technology designation and requested Sarepta voluntarily halt shipments of its approved drug Elevidys, which the company refused to do. Newsweek reached out to Sarepta Therapeutics via email on Sunday after normal business hours for comment. Why It Matters This regulatory intervention represents a significant safety measure in the gene therapy field, affecting both ongoing clinical trials and an already approved treatment for Duchenne muscular dystrophy. The decision could impact treatment options for families dealing with these devastating muscle-wasting diseases. Duchenne muscular dystrophy is a rare and serious genetic condition that worsens over time, leading to weakness and wasting away of the body's muscles. What To Know The three deaths resulted from acute liver failure in patients treated with either Elevidys or investigational therapies using the same AAVrh74 viral vector technology. One fatality occurred during a clinical trial for limb girdle muscular dystrophy treatment. Elevidys is an adeno-associated virus vector-based gene therapy designed to deliver a gene that leads to production of a shortened protein that contains selected domains of the dystrophin protein present in normal muscle cells. The disease occurs due to a defective gene that results in abnormalities in, or absence of, dystrophin, a protein that helps keep the body's muscle cells intact. The drug received traditional approval for ambulatory DMD patients aged 4 and older on June 20, 2024, while maintaining accelerated approval for non-ambulatory patients since June 22, 2023. Under accelerated approval, companies must conduct confirmatory studies to verify clinical benefit. Given the new safety concerns, the FDA has notified Sarepta that the drug's indication should be restricted to ambulatory patients only. The FDA revoked the platform technology designation for Sarepta's AAVrh74 Platform Technology because the preliminary evidence is insufficient to demonstrate that the technology has the potential to be incorporated in multiple drugs without adverse safety effects. What People Are Saying FDA Commissioner Marty Makary, M.D., M.P.H.: "Today, we've shown that this FDA takes swift action when patient safety is at risk. We believe in access to drugs for unmet medical needs but are not afraid to take immediate action when a serious safety signal emerges." Dr. Vinay Prasad, Director of FDA's Center for Biologics Evaluation and Research: "Protecting patient safety is our highest priority, and the FDA will not allow products whose harms are greater than benefits. The FDA will halt any clinical trial of an investigational product if clinical trial participants would be exposed to an unreasonable and significant risk of illness or injury." FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. FILE - The Food and Drug Administration seal is seen at the Hubert Humphrey Building Auditorium in Washington, Tuesday, April 22, 2025. AP Photo/Jose Luis Magana, File What Happens Next The FDA will continue investigating the risk of acute liver failure and other serious outcomes following gene therapies using Sarepta's AAVrh74 platform technology. The agency has committed to taking additional regulatory actions as needed to protect patients. For current Elevidys patients, the FDA is focusing its safety investigation on ambulatory patients while restricting the drug's use in non-ambulatory patients.
New York Post
6 hours ago
- New York Post
World's largest cruise ship heads to Florida ahead of August maiden voyage
The largest cruise ship in the world that's anticipated to become the crown jewel of Royal Caribbean's sprawling fleet will be docking in Florida before it departs on its first-ever voyage in late August. The 'Star of the Seas' ship, complete with 20 decks and a mind-boggling capacity for 5,000 passengers, set sail from its construction port in Finland on Thursday and is set to arrive at Florida's Port Canaveral on Aug. 15, according to its website. 3 Royal Caribbean's 'Star of the Seas' will embark on its maiden voyage on Aug. 31. Royal Caribbean Advertisement The ship is set to embark on its maiden voyage on Aug. 31. In the meantime, staff at Port Canaveral are battening down the hatches as they prepare for the thousands of tourists it will attract. After departing from the Orlando dock, the ship will make stops in the eastern and western ends of the Caribbean, including San Juan, St. Kitts, Cozumel and access to Royal Caribbean's private island in the Bahamas. 3 The luxury cruise will dock in Florida. Royal Caribbean Advertisement Such luxury comes at a hefty price, though. The cheapest ticket starts at $951 per person. The experience boasts a laundry list of activities free of extra charge, including access to the largest waterpark at sea and even a taste of Broadway through rotating performances of 'Back to the Future: The Musical,' according to its website. 3 The tickets come at a hefty cost. Royal Caribbean For the last 22 years, Royal Caribbean has been voted Best Overall by Travel Weekly readers.
Newsweek
10 hours ago
- Newsweek
Howard Lutnick Claims Tariffs Will Spark Up to 1.5 GDP Growth
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. During an interview appearance on CBS News' Face the Nation on Sunday, Commerce Secretary Howard Lutnick said President Donald Trump's sweeping new tariffs would drive as much as 1.5 percent gross domestic product (GDP) growth and open hundreds of billions in export opportunities. Lutnick also outlined the administration's timeline for renegotiating major trade deals, challenged European threats of retaliatory tariffs, and accused Federal Reserve chair Jerome Powell of inflicting economic pain on Americans through high interest rates. Why It Matters The Trump administration's latest round of tariffs—including a general 10 percent levy on U.S. imports and even higher rates on key trading partners—marks an expansion of trade policy intended to address longstanding U.S. trade deficits. Business and policy analysts have expressed concern about the impact tariffs would have since they're expected to lead to higher prices on imported goods, which could spur inflation and potentially dampen consumer spending. What To Know Lutnick projected that the new tariffs and subsequent trade negotiations could deliver between $300 and $400 billion of opportunity. "That's up to 1.5 percent GDP growth because the president's going to open all these markets up," he told host Margaret Brennan. The commerce secretary added that Trump's tariffs would force countries across the globe to "open their markets" to the U.S., which would allow American businesses to expand and sell overseas. "You should assume that the small countries, the Latin American countries, the Caribbean countries, many countries in Africa, they will have a baseline tariff of 10 percent, and then the bigger economies will either open themselves up or they'll pay a fair tariff to America," Lutnick said. The commerce secretary confirmed that Trump administration's August 1 tariffs deadline remained firm, and most major U.S. trading partners can expect to see a significant rise in their tariff rate. However, Lutnick said the U.S. was still open to negotiations after the deadline passes. "President Trump is going to deliver for the American people. [The] next two weeks are going to be weeks for the record books," he added. Meanwhile, Mark Zandi, chief economist at Moody's Analytics, told ABC News on Saturday that he believed tariff revenue could exceed $300 billion by the end of 2025, nearly 1 percent of U.S. GDP. However, he added that "it would not be prudent for lawmakers to count on this revenue in the future." "It is unclear whether the tariffs will remain in place given they may be found to be illegal or future presidents may decide to lower or eliminate them under executive order," Zandi said. Commerce Secretary Howard Lutnick is seen in the East Room of the White House on July 18 in Washington, D.C. Commerce Secretary Howard Lutnick is seen in the East Room of the White House on July 18 in Washington, D.C. Alex Brandon/AP Lutnick Reveals Timeline for Trump Renegotiating USMCA Deal Lutnick told Brennan that Trump intends to renegotiate the United States-Mexico-Canada Agreement (USMCA) when the agreement comes up for review. The agreement was signed in 2020 to facilitate trade and stimulate economy and job growth in North America. He added that Trump will begin renegotiating one year from now, with the aim of securing greater market access for U.S. businesses and protecting American manufacturing jobs. "It makes perfect sense for the president to renegotiate it," he said. "He wants to protect American jobs. He doesn't want cars built in Canada or Mexico when they can be built in Michigan and Ohio," Lutnick said. Lutnick Suggests Europe Will Cave Over Tariff Threats to Boeing, Bourbon Lutnick addressed retaliatory threats from Europe targeting American goods during the interview. The European Union (EU) has finalized a list of U.S. goods worth $84 billion, including Boeing aircraft, American cars and bourbon, that they will hit with retaliatory tariffs if the trade war escalates. Lutnick said he was confident the EU would cave and open their market to the U.S. before it got to that point. "The president and the European Union, these are the two biggest trading partners in the world, talking to each other. We'll get a deal done. I am confident we'll get a deal done," he said. Jerome Powell 'Torturing' America, Says Lutnick Lutnick sharply criticized Powell for maintaining high interest rates, which he said costs "us, you and me and the American people, more than $500 billion." "I think he's costing us $700 billion a year by keeping rates too high. It's just wrong. I don't know why he's torturing America this way. Our rates should be lower." He predicted the Fed would be forced to lower rates, making mortgages "so much better off under Donald Trump." What People Are Saying Peter Schiff, chief economist and global strategist for Europac, wrote on X, formerly Twitter, on last month: "Tariffs are not working. The U.S. trade deficit in goods surged to $96.6 billion in May, up 11% from April and 6.5% above expectations. Most problematic was the 5.2% decline in exports. Trump's goal to reduce trade deficits while expanding markets for U.S. exports has backfired." Brad Setser, an economist at the New York City-based Council on Foreign Relations, recently wrote on X: "I am not yet seeing a significant tariff impact on trade in capital goods -- and I do think the ongoing rise in the US deficit here is a problem (capital goods are a sector where the US should be competitive)." Denmark's foreign minister, Lars Løkke Rasmussen, told reporters this week after Brussels suspended its retaliatory tariffs on U.S. goods in hopes of reaching a trade deal: "We shouldn't impose countermeasures at this stage, but we should prepare to be ready to use all the tools in the toolbox. So we want a deal, but there's an old saying: 'If you want peace, you have to prepare for war.'" What Happens Next? The full economic and political consequences of the tariffs will likely unfold in the coming months, as the impact on trade balances, job growth, and consumer prices becomes clearer.
